Aug. 7, 2024
The Advanced Research Projects Agency for Health (ARPA-H) within the U.S. Department of Health and Human Services recently announced the Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program. GLIDE aims to develop physical, pharmacologic, gene and cell-based therapeutic interventions to treat primary and rare lymphatic disease (LD) and chronic conditions complicated by lymphatic dysfunction.

GLIDE’s goals are spread across two technical areas for developing new physical and pharmacological therapies targeting abnormal lymphatic structure and function. Through advances in biomaterials, interventional radiology (IR) and minimally invasive surgical approaches and imaging, GLIDE will accelerate therapeutic options in compression, IR, microsurgery, and other minimally invasive technologies. Additionally, GLIDE will support the development of targeted pharmacologic gene and cell therapies that directly target mechanisms of lymphatic dysfunction to modulate tissue contractility and vessel growth.

For more information on the GLIDE program, ARPA-H will host a Hybrid Proposers' Day Sept. 17.

For more information about American College of Radiology® (ACR®) collaborations with ARPA-H, contact Katie Grady, ACR Government Affairs Director.

Related ACR News

  • ACR 2025 Economics Forum

    The Economics Forum at ACR 2025 highlighted recent successes including coverage of CT colonoscopy for Medicare patients and new CPT codes for MRI safety.

    Read more
  • Radiology Advocacy Begins Now

    Medical student, Annie Pham, BS, M3 of Edward Via College of Osteopathic Medicine, Louisiana Campus, discusses her experiences during the 2025 ACR Capitol Hill Day.

    Read more
  • Connections Through Advocacy: Familiar Faces Along the Interview Trail

    Read more